Commodore Capital Reports 7.7% Stake in Enliven Therapeutics, Inc.

Commodore Capital LP, along with Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson, filed a Schedule 13G/A on May 15, 2026, reporting a 7.7% ownership stake in Enliven Therapeutics, Inc. (ELVN). As of the event date on March 31, 2026, the filers collectively beneficially own 4,800,940 shares of Common Stock. This position includes 3,275,000 shares of Common Stock held directly and 1,525,940 shares issuable upon the exercise of pre-funded warrants. The exercise of these warrants is subject to a 9.99% beneficial ownership limitation. Commodore Capital LP serves as the investment manager to Commodore Capital Master LP, while Michael Kramarz and Robert Egen Atkinson are the managing partners who exercise investment discretion over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This filing represents an increase from a previously reported 0% position, establishing a significant minority interest in the biotechnology company.